Subscribe

CanSino Biologics Inc. (688185.SS)

CNY52.95 +2.50 (+4.96%)
CN SHH Healthcare Biotechnology
Address 401-420, Biomedical Park 300457
Tianjin, BJ, CN
CEO Xue Feng Yu
Website cansinotech.com
IPO 2020-08-13
ISIN CNE100004BM0

Explore sections of this company profile

Also trades on Hong Kong Stock Exchange · 6185.HK (HKD) Other OTC · CASBF (USD) Shanghai Stock Exchange · 688185.SS (CNY)
Description

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. In addition, it develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. Further, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CS-2023 to treat meningitis; CS-2028 for treating multivalent conjugate vaccine; CS-2032 for hingles; CS-2036 to treat polio; CS-2047 for treating tetanus; and CS-2201 DTcP for combination vaccine. The company was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
CNY52.95 +2.50 (+4.96%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
1.16
Float Shares
88.04M
Free Float %
48.2%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+1.11% -8.52% -4.81% -18.68% -14.46% -6.84% -0.24% -34.97% -89.97% -85.11% -85.11%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
52.95
Ratings Trend (MoM)
Rating 2024-11 Change
Strong Buy 0 0
Buy 0 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
3.64
Safe zone
Piotroski F-Score
5 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
  • ✓
    Revenue growth Biotechnology: +1.6%
    +26.2% ★ Q1'26: +38.7% (vs Q1'25)
  • ✓
    EPS growth Biotechnology: +29.7%
    +107.2% ★ Q1'26: -220.0% (vs Q1'25)
  • ✗
    FCF margin FCF growth · Biotechnology: +16.2%
    -7.0% Q1'26: -47.0% (vs Q1'25)
  • ✗
    EBIT margin Biotechnology: +0.0%
    +5.7% ★ Q1'26: -22.2% (vs Q1'25)
  • ✗
    ROIC Biotechnology: -16.1%
    +1.7% ★ Q1'26: -4.2% (vs Q1'25)
  • ✗
    Share dilution Biotechnology: -3.4%
    +2.3% ★ Q1'26: +7.0% (vs Q1'25)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×
    5.41× ★ Q1'26: -6.89× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (1.16) × ERP
WACC = 92% × Ke + 8% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Current price: 52.95
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
3 Rev. Ana.
1 EPS Ana. 		Dec 2027
3 Rev. Ana.
1 EPS Ana. 		Dec 2028
1 Rev. Ana.
1 EPS Ana. 		Dec 2029
2 Rev. Ana.
1 EPS Ana.
Revenue
15.61M
est: 2.28M (+583.8%)
24.89M
est: 11.54M (+115.7%)
4.30B
est: 5.49B (-21.7%)
1.03B
est: 1.06B (-2.4%)
357.08M
est: 369.14M (-3.3%)
846.34M
est: 836.86M (+1.1%)
1.07B
est: 1.06B (+0.7%)
1.43B
1.41B – 1.47B
+34.8% YoY
1.77B
1.68B – 1.89B
+23.5% YoY
2.20B
2.13B – 2.32B
+24.9% YoY
2.75B
2.65B – 2.89B
+24.6% YoY
EBITDA
-131.40M
est: -1.28M (-10,181.1%)
-377.73M
est: -6.46M (-5,746.9%)
2.02B
est: -3.08B (+165.8%)
-962.04M
est: -593.52M (-62.1%)
-1.67B
est: -206.65M (-710.5%)
-135.62M
est: -233.80M (+42.0%)
238.03M
est: -296.28M (+180.3%)
-399.41M
-410.69M – -393.35M
-34.8% YoY
-493.30M
-526.86M – -468.84M
-23.5% YoY
-616.02M
-647.07M – -594.87M
-24.9% YoY
-767.33M
-806.02M – -740.99M
-24.6% YoY
EBIT
-147.78M
est: -1.39M (-10,570.2%)
-396.64M
est: -7.00M (-5,565.5%)
1.96B
est: -3.33B (+158.7%)
-1.14B
est: -643.19M (-77.6%)
-1.92B
est: -223.94M (-755.3%)
-321.05M
est: -312.43M (-2.8%)
61.35M
est: -395.93M (+115.5%)
-533.75M
-548.82M – -525.64M
-34.8% YoY
-659.21M
-704.07M – -626.53M
-23.5% YoY
-823.20M
-864.70M – -794.94M
-24.9% YoY
-1.03B
-1.08B – -990.21M
-24.6% YoY
Net Income
-156.77M
est: -190.68M (+17.8%)
-396.64M
est: -411.49M (+3.6%)
1.91B
est: 2.52B (-23.9%)
-909.43M
est: -414.79M (-119.2%)
-1.48B
est: -1.26B (-17.5%)
-378.88M
est: -289.46M (-30.9%)
27.87M
est: 27.87M (+0.0%)
93.82M
89.64M – 99.97M
+236.6% YoY
247.82M
236.76M – 264.06M
+164.1% YoY
307.23M
293.52M – 327.37M
+24.0% YoY
913.50M
872.73M – 973.36M
+197.3% YoY
SGA
67.62M
est: 3.14M (+2,056.7%)
95.43M
est: 15.85M (+502.1%)
326.62M
est: 7.54B (-95.7%)
535.48M
est: 1.46B (-63.2%)
639.88M
est: 506.96M (+26.2%)
547.75M
est: 600.03M (-8.7%)
589.83M
est: 760.39M (-22.4%)
1.03B
1.01B – 1.05B
+34.8% YoY
1.27B
1.20B – 1.35B
+23.5% YoY
1.58B
1.53B – 1.66B
+24.9% YoY
1.97B
1.90B – 2.07B
+24.6% YoY
EPS
-0.77
est: -0.77 (+0.0%)
-1.72
est: -1.66 (-3.5%)
7.74
est: 10.16 (-23.8%)
-3.68
est: -1.68 (-119.7%)
-6.01
est: -5.10 (-17.9%)
-1.53
est: -1.14 (-33.9%)
0.11
est: 0.11 (+0.0%)
0.37
0.35 – 0.39
+236.6% YoY
0.98
0.93 – 1.04
+164.1% YoY
1.21
1.16 – 1.29
+24.0% YoY
3.61
3.44 – 3.84
+197.3% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 C- 1/5 1/5 1/5 1/5 2/5 1/5 2/5
2026-05-28 C- 1/5 1/5 1/5 1/5 2/5 1/5 2/5
2026-05-27 C- 1/5 1/5 1/5 1/5 2/5 1/5 2/5
2026-05-26 C- 1/5 1/5 1/5 1/5 2/5 1/5 2/5
2026-05-25 C- 1/5 1/5 1/5 1/5 2/5 1/5 2/5
2026-05-22 C- 1/5 1/5 1/5 1/5 2/5 1/5 2/5
2026-05-21 C- 1/5 1/5 1/5 1/5 2/5 1/5 2/5
2026-05-20 C- 1/5 1/5 1/5 1/5 2/5 1/5 2/5
2026-05-19 C- 1/5 1/5 1/5 1/5 2/5 1/5 2/5
2026-05-18 C- 1/5 1/5 1/5 1/5 2/5 1/5 2/5
2026-05-15 C- 1/5 1/5 1/5 1/5 2/5 1/5 2/5
2026-05-14 C- 1/5 1/5 1/5 1/5 2/5 1/5 2/5
2026-05-13 C- 1/5 1/5 1/5 1/5 2/5 1/5 2/5
2026-05-12 C- 1/5 1/5 1/5 1/5 2/5 1/5 2/5
2026-05-11 C- 1/5 1/5 1/5 1/5 2/5 1/5 2/5
2026-05-08 C- 1/5 1/5 1/5 1/5 2/5 1/5 2/5
2026-05-07 C- 1/5 1/5 1/5 1/5 2/5 1/5 2/5
2026-05-06 C- 1/5 1/5 1/5 1/5 2/5 1/5 2/5
2026-04-30 C- 1/5 1/5 1/5 1/5 2/5 1/5 2/5
2026-04-29 C- 1/5 1/5 1/5 1/5 2/5 1/5 2/5
2026-04-28 C+ 2/5 1/5 2/5 4/5 2/5 1/5 2/5
2026-04-27 C+ 2/5 1/5 2/5 4/5 2/5 1/5 2/5
2026-04-24 C 2/5 1/5 2/5 4/5 1/5 1/5 2/5
2026-04-23 C 2/5 1/5 2/5 4/5 1/5 1/5 2/5
2026-04-22 C 2/5 1/5 2/5 4/5 1/5 1/5 2/5
2026-04-21 C 2/5 1/5 2/5 4/5 1/5 1/5 2/5
2026-04-20 C 2/5 1/5 2/5 4/5 1/5 1/5 2/5
2026-04-17 C 2/5 1/5 2/5 4/5 1/5 1/5 2/5
2026-04-16 C 2/5 1/5 2/5 4/5 1/5 1/5 2/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
43.23M
OE per share TTM
0.03
Owner's Yield
0.30%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
165.0%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock Held by 14 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 Vanguard FTSE Emerging Markets Shares ETF VGE.AX 0.00% 4.1K 0.48%
2 Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO 0.00% 9.3K 0.26%
3 Vanguard FTSE Emerging Markets ETF VWO 0.00% 460.3K 0.06%
4 Vanguard All-World ex-US Shares Index ETF VEU.AX 0.00% 8.5K 0.04%
5 Vanguard Total International Stock ETF VXUS 0.00% 1.27M 0.05%
6 Vanguard FTSE All-World ex-US ETF VEU 0.00% 183.5K 0.04%
7 Vanguard Total World Stock ETF VT 0.00% 47.2K 0.06%
8 Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO 0.00% 739.82 0.22%
9 Vanguard All-Equity ETF Portfolio VEQT.TO 0.00% 2.2K 0.22%
10 Vanguard Growth ETF Portfolio VGRO.TO 0.00% 1.2K 0.22%

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
54.1K
Shares Outstanding
182.59M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Tao Zhu Co-Founder, Deputy GM & Chief Scientific Officer 4M —
Xuefeng Yu Co-Founder, Executive Chairman, Chief Executive Officer & GM 4M —
Dongxu Qiu Co-Founder, Executive Vice President & Deputy GM 4M —
Jing Wang Chief Commercial Officer, Deputy GM & Executive Director 3M female
Shou-Bai Chao Chief Operating Officer, Deputy GM & Executive Director 3M —
Bei Bei Gao Accounting Supervisor — —
Yonghui Wu Vice President of Marketing — male
Chunlin Xin Senior Director of New Technology Department — male
Jin Cui Board Secretary — male
Ming King Chiu FCIS Joint Company Secretary — male
Ming Liu Acting Head of Finance — —
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Biotechnology